NXL$1.50-0.35%
Nexalin Technology, Inc.
Sector: Electromedical & Electrotherapeutic ApparatusIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Mkt Cap:$1.57M
Float & O/S:
Inst Own:
DilutionScan read 43 of Nexalin Technology, Inc.'s SEC filings and found 3 warrant series, 1 ATM program, 1 equity line, 2 shelf registrations, 3 S-1 registrations and 2 completed offerings on file for NXL. The latest dilution event on file is a registration statement on Oct 15, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
NXL
Going-concern warning, Nasdaq delisting risk
Snapshot
Nexalin is a pre-commercial medical device maker with just $302K in FY 2025 revenue against a $8.2M net loss, over 25 times revenue. Gross margin is a healthy 80%, but sales & marketing alone ran 20x revenue.
What's Happening Right Now
- : On Oct 1, 2026, Nexalin signed a 10-year exclusive distribution and local manufacturing agreement for Brazil and South America, with a binding initial order for 10 devices and a planned 100-device program.
- : On Sept 25, 2026, the Nasdaq Hearings Panel granted continued listing but set strict deadlines: $1.00 minimum bid by Sept 28, 2026 and $2.5M stockholders' equity by Jan 4, 2027, with no assurance of compliance.
- : On Sept 10, 2026, Nexalin priced a $750K registered direct offering at $0.31/share with attached warrants, plus a $15M equity line, days before its Nasdaq hearing, against a $97.2M accumulated deficit.
- : On Aug 21, 2026, Nexalin issued a $1.17M note to Streeterville Capital with only $1M net proceeds after discounts, carrying punitive default terms and mandatory prepayments from future fundraising.
- : Q2 2026 revenue fell 83% YoY to $12,161, the six-month net loss widened to $4.3M, and management disclosed substantial doubt about the company's ability to continue as a going concern.
